ClinicalTrials.gg
RecruitingNCT07426016VID LISAUpdated Jun 15, 2026

Video vs. Direct Laryngoscopy for Less Invasive Surfactant Administration

An interventional study of Video Laryngoscopy and Direct Laryngoscopy in Respiratory Distress Syndrome (Neonatal) and Surfactant Deficiency Syndrome Neonatal, sponsored by University of Texas Southwestern Medical Center. Recruiting at 1 site in United States. Open to participants aged 0 Hours to 3 Days. Per ClinicalTrials.gov, last updated 2026-06-15.

Sponsored by University of Texas Southwestern Medical Center · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Jun 2026; still recruiting 5 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
100
Allocation
Randomized
Ages
0 Hours to 3 Days
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 43 studies in Pulmonary Atelectasis with a site in United States — 11 open to participants now, 11 under way, 1 of them phase 3. Pulmonary Atelectasis · United States.

Planned enrollment
12th of 37
100 · median 40
Started
2026
with 3 others
No phase
31 of 43
6 open now
Primary completion
2028-06
later than 6 of 10 live
Registered
42nd of 43
by date
Lead sponsor
3 of 43
University of Texas Southwestern Medical Center

Among the 43 studies in Pulmonary Atelectasis with a site in United States, this one is the 12th largest by planned enrollment of the 37 interventional ones that give a count, is one of 4 that started in 2026, is one of 31 with no phase, reaches primary completion later than 6 of the 10 other live ones, and was the 42nd registered.

Pulmonary Atelectasis

378 studies on the registry are indexed under Pulmonary Atelectasis; 91 are open to participants now.

Browse Pulmonary Atelectasis studies →

Open to participants now

11 of the 43 studies in Pulmonary Atelectasis with a site in United States are open now. Recruiting first, the newest first:

5 more — sign in →

All 11 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 51 Pulmonary Atelectasis studies recruiting now, 20 (39%) set no upper age limit and 23 (45%) stop at 75 or younger; 24 take children under 18; 2 take healthy volunteers.

This study: 0 Hours to 3 Days · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 43 studies in Pulmonary Atelectasis with a site in United States, or all of them as a file.
02

Study summary

Many preterm babies born between 22-28+6 weeks' estimated gestational age (EGA) need surfactant, a medicine that helps the lungs. The goal of the study is to compare the use of video-based visualization to direct visualization during a procedure called less invasive surfactant administration (LISA). The main questions the study aims to answer are: 1) does one method of visualization have a increased rate of giving the medicine successfully on the first attempt? 2) what benefits are there of each method?

03

Conditions studied

  • Respiratory Distress Syndrome (Neonatal)
  • Surfactant Deficiency Syndrome Neonatal

Browse trials for

Keywords

  • less invasive surfactant
  • neonatal
  • video laryngoscopy
04

Who can participate

Ages eligible
0 Hours to 3 Days
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Infants born ≤28 weeks GA successfully resuscitated in the delivery room (DR) and maintained on CPAP • Need for surfactant in the first 36 hours of life based on clinical assessment and/or meeting threshold per unit protocol

Exclusion criteria

Exclusion Criteria:

  • Infants born ≥29 weeks GA or
  • Infants with known congenital anomalies or
  • Infants who are determined by the primary care team to receive comfort care only or
  • Infants who are intubated at any time prior to surfactant administration
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
100 participants (estimated)

Study arms

  • Active comparator
    Video Laryngoscopy

    A video laryngoscopy will be used to visualize the vocal cords and place the LISA catheter for surfactant administration

    Procedure: Video Laryngoscopy

  • Active comparator
    Direct Laryngoscopy

    Direct laryngoscopy (no camera) will be used to visualize the vocal cords and place the LISA catheter for surfactant administration

    Procedure: Direct Laryngoscopy

Interventions

  • ProcedureVideo Laryngoscopy

    Video Laryngoscopy will be used to visualize the vocal cords and place the LISA catheter

  • ProcedureDirect Laryngoscopy

    Direct Laryngoscopy will be used to visualize the vocal cords and place the LISA catheter

06

What researchers measure

Primary outcomes

  1. Rate of first attempt success

    Time frame: During procedure

Secondary outcomes

  1. Duration of desaturation below 80% SpO2 (sec),

    Time frame: during procedure

  2. Duration of bradycardia (HR <100 bpm)

    Time frame: procedure duration

  3. Number of desaturation/bradycardia episodes

    Time frame: during procedure

  4. Number of surfactant installation attempts

    Time frame: during procedure

  5. Time to completion of surfactant installation

    Time frame: during procedure

  6. Time to insertion of thin catheter

    Time frame: during procedure

  7. Amount of surfactant in stomach at the end of the procedure

    Time frame: within 5 min after procedure

  8. Mean maximum fractioned inspired O2 used

    Time frame: during procedure

  9. Lowest oxygen saturation during catheter insertion

    Time frame: during procedure

  10. Fractionated inspired oxygen (FiO2) at 60 mins post procedure

    Time frame: 60 minutes post-procedure

  11. Lowest heart rate during catheter insertion

    Time frame: during procedure

  12. Cross over to alternative method

    Time frame: during procedure

  13. Incidence of intubation at 72 hours post surfactant administration

    Time frame: procedure to 72 hours post-procedure

  14. Incidence of pneumothorax

    Time frame: procedure to 72 hours post-procedure

  15. Incidence of severe (grade III/IV) intraventricular hemorrhage

    Time frame: Birth to discharge

  16. Continuous Positive Expiratory Pressure (CPAP) at 60 mins post procedure

    Time frame: 60 minutes post-procedure

  17. Intubation during procedure

    Time frame: During Procedure

  18. Change in provider during procedure

    Time frame: during procedure

  19. Survival to discharge or 90 days

    Time frame: up to 90 days

07

Study locations

1 of 1 sites recruiting
  • Parkland Hospital
    Dallas, Texas 75235, United States
    Recruiting
    • Office of Research Administration · Contactirb@utsouthwestern.edu · 214-645-8300
    • Riti Chokshi, MD · Principal investigator
    • Shalini Ramachandram, MD · Principal investigator
08

References and documents

Publications

  • Aldana-Aguirre JC, Pinto M, Featherstone RM, Kumar M. Less invasive surfactant administration versus intubation for surfactant delivery in preterm infants with respiratory distress syndrome: a systematic review and meta-analysis. Arch Dis Child Fetal Neonatal Ed. 2017 Jan;102(1):F17-F23. doi: 10.1136/archdischild-2015-310299. Epub 2016 Nov 15. PubMed 27852668 ↗
  • Kurepa D, Boyar V, Predtechenska O, Gupta V, Weinberger B, Pulju M, Zaytseva A, Galanti SG, Kasniya G, Perveen S. Video laryngoscopy-assisted less-invasive surfactant administration quality improvement initiative. Arch Dis Child Fetal Neonatal Ed. 2023 Nov;108(6):588-593. doi: 10.1136/archdischild-2023-325357. Epub 2023 Apr 7. PubMed 37028921 ↗
  • Riva T, Engelhardt T, Basciani R, Bonfiglio R, Cools E, Fuchs A, Garcia-Marcinkiewicz AG, Greif R, Habre W, Huber M, Petre MA, von Ungern-Sternberg BS, Sommerfield D, Theiler L, Disma N; OPTIMISE Collaboration. Direct versus video laryngoscopy with standard blades for neonatal and infant tracheal intubation with supplemental oxygen: a multicentre, non-inferiority, randomised controlled trial. Lancet Child Adolesc Health. 2023 Feb;7(2):101-111. doi: 10.1016/S2352-4642(22)00313-3. Epub 2022 Nov 24. PubMed 36436541 ↗
  • Geraghty LE, Dunne EA, Ni Chathasaigh CM, Vellinga A, Adams NC, O'Currain EM, McCarthy LK, O'Donnell CPF. Video versus Direct Laryngoscopy for Urgent Intubation of Newborn Infants. N Engl J Med. 2024 May 30;390(20):1885-1894. doi: 10.1056/NEJMoa2402785. Epub 2024 May 5. PubMed 38709215 ↗
  • Garcia-Marcinkiewicz AG, Kovatsis PG, Hunyady AI, Olomu PN, Zhang B, Sathyamoorthy M, Gonzalez A, Kanmanthreddy S, Galvez JA, Franz AM, Peyton J, Park R, Kiss EE, Sommerfield D, Griffis H, Nishisaki A, von Ungern-Sternberg BS, Nadkarni VM, McGowan FX Jr, Fiadjoe JE; PeDI Collaborative investigators. First-attempt success rate of video laryngoscopy in small infants (VISI): a multicentre, randomised controlled trial. Lancet. 2020 Dec 12;396(10266):1905-1913. doi: 10.1016/S0140-6736(20)32532-0. PubMed 33308472 ↗

Individual participant data

Plan to share: Undecided

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2026 (actual). Primary completion is estimated for Jun 2028, 24 months after the start.

Of 155 non-industry interventional studies with no phase under Pulmonary Atelectasis, half reached primary completion within 11 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 24. This study's planned 24 months is above that.

Counting every sponsor, half of 157 studies reached it within 11 months; a quarter within 5 and three quarters within 21.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 16, 2026
First posted
Feb 23, 2026
StartActual
Jun 11, 2026
Primary completionEst.
Jun 2028
CompletionEst.
Nov 2028
Last update
Jun 15, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 15, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07426016
Responsible party
Riti Chokshi, MD (Assistant Professor, University of Texas Southwestern Medical Center) — Principal investigator
First posted
Feb 23, 2026
Start date
Jun 11, 2026
Primary completion
Jun 2028 (estimated)
Completion
Nov 2028 (estimated)
Last update
Jun 15, 2026

Study contacts

Principal Investigator, MD
Contact
riti.chokshi@utsouthwestern.edu
214-648-3383
Chokshi, MD
principal investigator · UT Southwestern
Shalini Ramachandran, MD
principal investigator · UT Southwestern

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion